700 mg leronlimab

DRUG2 trials

Sponsors

CytoDyn, Inc.

Conditions

Metastatic Colorectal Cancer (mCRC)Triple Negative Breast Neoplasms

Phase 1

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

TerminatedNCT03838367

CytoDyn, Inc.Triple Negative Breast Neoplasms

Start: 2019-04-22End: 2022-09-16Updated: 2025-09-09

Phase 2

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

Active, not recruitingNCT06699836

CytoDyn, Inc.Metastatic Colorectal Cancer (mCRC)

Start: 2025-06-16End: 2028-03-01Updated: 2026-09-09

Related Papers

Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.

Journal of Clinical Oncology2026-05-28

Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.

Journal of Clinical Oncology2026-05-28

Abstract B019: CCR5 inhibition with leronlimab is associated with enhanced PD-L1 expression, ICI response, and long-term survival in metastatic TNBC.

Cancer Immunology Research2025-09-24

Abstract CT156: Changes in circulating tumor associated cells predicts progression free and overall survival in metastatic TNBC patients after induction of the anti-CCR5 drug leronlimab

Cancer Research2022-06-151 citations

Safety, efficacy, and clinical outcomes of the anti-CCR5 inhibitor (Leronlimab): A pooled analysis of three clinical trials in patients with mTNBC.

Journal of Clinical Oncology2022-06-0111 citations

Abstract P5-17-08: A phase Ib/II study of leronlimab combined with carboplatin in patients with CCR5+ metastatic triple-negative breast cancer (mTNBC)

Cancer Research2022-02-157 citations

Abstract PD4-04: Leronlimab, a humanized monoclonal antibody to CCR5, restrains breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapies

Cancer Research2020-02-153 citations